• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Real-world efficacy and safety of dupilumab use in the treatment of asthma.

作者信息

Nowsheen Somaira, Darveaux Jared I

机构信息

Gundersen Lutheran Medical Foundation, La Crosse, Wisconsin.

Department of Allergy and Immunology, Gundersen Health System, Onalaska, Wisconsin.

出版信息

Ann Allergy Asthma Immunol. 2021 Jul;127(1):147-149. doi: 10.1016/j.anai.2021.04.011. Epub 2021 Apr 10.

DOI:10.1016/j.anai.2021.04.011
PMID:33848633
Abstract
摘要

相似文献

1
Real-world efficacy and safety of dupilumab use in the treatment of asthma.度普利尤单抗用于治疗哮喘的真实世界疗效和安全性。
Ann Allergy Asthma Immunol. 2021 Jul;127(1):147-149. doi: 10.1016/j.anai.2021.04.011. Epub 2021 Apr 10.
2
Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort.度普利尤单抗治疗法国多中心成年患者真实队列中重度哮喘的有效性和安全性
Clin Exp Allergy. 2020 Jul;50(7):789-798. doi: 10.1111/cea.13614. Epub 2020 May 29.
3
Omalizumab in patients with severe asthma: the XCLUSIVE study.奥马珠单抗治疗重度哮喘患者：XCLUSIVE研究
Clin Respir J. 2012 Oct;6(4):215-27. doi: 10.1111/j.1752-699X.2011.00263.x. Epub 2011 Aug 9.
4
One-year real-world clinical effectiveness, safety, and laboratory safety of dupilumab in Japanese adult patients with atopic dermatitis: A single-center retrospective study.度普利尤单抗在日本成年特应性皮炎患者中的一年真实世界临床疗效、安全性及实验室安全性：一项单中心回顾性研究。
J Am Acad Dermatol. 2021 Feb;84(2):547-550. doi: 10.1016/j.jaad.2020.05.102. Epub 2020 May 29.
5
Omalizumab under 12 years old: real-life practice.
Allergol Immunopathol (Madr). 2013 Mar-Apr;41(2):133-6. doi: 10.1016/j.aller.2012.01.008. Epub 2012 May 3.
6
Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.美泊利珠单抗在日本重度嗜酸性粒细胞性哮喘患者中的疗效和安全性。
Allergol Int. 2017 Jul;66(3):445-451. doi: 10.1016/j.alit.2016.11.006. Epub 2017 Jan 16.
7
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.度普利尤单抗治疗伴有鼻息肉的重度慢性鼻-鼻窦炎患者的疗效和安全性（LIBERTY NP SINUS-24 和 LIBERTY NP SINUS-52）：两项多中心、随机、双盲、安慰剂对照、平行分组 3 期临床试验的结果。
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
8
Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials.度普利尤单抗在未控制哮喘中的安全性和有效性：随机临床试验的系统评价和荟萃分析
J Asthma. 2019 Oct;56(10):1110-1119. doi: 10.1080/02770903.2018.1520865. Epub 2018 Oct 1.
9
Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.度普利尤单抗治疗日本特应性皮炎患者的真实世界有效性和安全性：一项单中心回顾性研究
Br J Dermatol. 2019 Nov;181(5):1083-1085. doi: 10.1111/bjd.18163. Epub 2019 Aug 22.
10
Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials.度普利尤单抗治疗未控制哮喘的疗效和安全性：随机临床试验的荟萃分析。
Respir Res. 2019 May 31;20(1):108. doi: 10.1186/s12931-019-1065-3.

引用本文的文献

1
Efficacy Assessment of Biological Treatments in Severe Asthma.重症哮喘生物治疗的疗效评估
J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.
2
Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.严重哮喘的个体化医学：从生物标志物到生物制剂。
Int J Mol Sci. 2023 Dec 22;25(1):182. doi: 10.3390/ijms25010182.
3
[Consensus document for severe asthma in adults. 2022 update].[成人重度哮喘共识文件。2022年更新]
Open Respir Arch. 2022 Jul 2;4(3):100192. doi: 10.1016/j.opresp.2022.100192. eCollection 2022 Jul-Sep.
4
Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry.现实世界中接受度普利尤单抗治疗的哮喘患者：RAPID 全球注册研究。
Adv Ther. 2023 Mar;40(3):1292-1298. doi: 10.1007/s12325-022-02399-5. Epub 2023 Jan 10.
5
Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma.重症支气管哮喘抗体治疗的进展与挑战
Int J Mol Sci. 2021 Dec 22;23(1):83. doi: 10.3390/ijms23010083.
6
Reduced exacerbation frequency and prednisone dose in patients with ABPA and asthma treated with dupilumab.使用度普利尤单抗治疗的ABPA和哮喘患者的病情加重频率和泼尼松剂量降低。
Clin Transl Allergy. 2021 Dec;11(10):e12081. doi: 10.1002/clt2.12081.
7
Recent Insights into the Management of Inflammation in Asthma.哮喘炎症管理的最新见解
J Inflamm Res. 2021 Sep 2;14:4371-4397. doi: 10.2147/JIR.S295038. eCollection 2021.